REVOLUTION Medicines' first drug candidates exploit and improve upon the properties of amphotericin B, a powerful, broad-spectrum antifungal compound found in nature that has avoided generating significant drug resistance in 50 years of clinical use. Full therapeutic benefit from this highly efficacious natural compound is significantly compromised by inherent dose-limiting side effects, principally kidney damage. REVOLUTION Medicines is developing novel compounds that leverage the proven therapeutic mechanism for killing fungi while minimizing toxic effects on human cells.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/04/15	$45,000,000	Series A	Third Rock Ventures	undisclosed
12/21/16	$25,000,000	Series A Extension	The Column Group Third Rock Ventures	undisclosed
07/09/19	$100,000,000	Series C	Biotechnology Value Fund Boxer Capital Casdin Capital Cormorant Capital Deerfield Management Company, L.P. Fidelity Management & Research Company Nextech Invest Schroder Adveq The Column Group Third Rock Ventures Vivo Capital	undisclosed